Immune thrombocytopenia: An updated review from etiopathophysiology, laboratory investigations and current therapy

Dr. Avijit Mazumder  
Director & Professor, Noida Institute of Engineering & Technology (Pharmacy Institute), Greater Noida  
Email: avijitmazum@yahoo.com  
ORCID - 0000-0002-3053-8106

Dr. Saumya Das  
Associate Professor, Noida Institute of Engineering & Technology (Pharmacy Institute), Greater Noida  
Corresponding author email: awasthi.saumya22@gmail.com  
ORCID – 0000-0002-8531-9963

Ayush Atri  
Master of Pharmacy (Persuing) from Noida Institute of Engineering & Technology (Pharmacy Institute), Greater Noida, Bachelor Of Pharmacy, Raj Kumar Goel Institute Of Technology, Ghaziabad  
Email: ayushatri06@gmail.com  
ORCID 0000-0003-4499-6869

Komal Singh  
Master of Pharmacy (Persuing) from Noida Institute of Engineering & Technology (Pharmacy Institute), Greater Noida, Bachelor Of Pharmacy, Raj Kumar Goel Institute Of Technology, Ghaziabad  
Email: komalsinghghahlot440@gmail.com  
ORCID- 0000-0001-7807-0357

Madhvi Singh  
Master of Pharmacy (Persuing) from Noida Institute of Engineering & Technology (Pharmacy Institute), Greater Noida, Bachelor Of Pharmacy, Brahmanand Group Of Institutions, Bulandshahr  
Email: madhvithakur12599@gmail.com  
ORCID- 0000-0003-1396-7731

Abstract—An inherited condition with isolated thrombocytopenia, immune thrombocytopenia (ITP) is still unknown in terms of the cause. A primary or secondary ITP diagnosis is determined by whether or not an underlying treatable cause exists. Diagnosis of primary ITP
is based on the exclusion and hence does not have a gold standard test to validate it. Before classifying a patient as primary ITP, recent medication use, infections, lymphoproliferative illnesses, and connective tissue disorders should be checked out. An in-depth look at the most recent developments in ITP diagnostics and treatment is provided in this study. Our research was supported by GOOGLE Scholar, PUBMED, and ClinicalTrial.gov databases. Idiopathic thrombocytopenic purpura was also included in the search, as was "immune-mediated thrombocytopenia," "idiopathic thrombocytopenic purpura," and "isolated thrombocytopenia." It was found that more research is needed to better understand the underlying mechanisms of ITP. For example, corticosteroids have both short- and long-term side effects when used in the first place. In light of this, future research may need a rethinking of ITP treatment recommendations and the use of viable alternative drugs.

**Keywords**—Isolated Thrombocytopenia, Diagnosis, primary, immune-mediated.

**Introduction**

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder that is characterized by an isolated low platelet count of less than $100 \times 10^9/L$ (2). Although the exact pathogenesis is unknown, it is believed to result from autoimmune destruction of platelets due to the formation of antiplatelet autoantibodies and decreased platelet production arising from defective megakaryopoiesis. As per the literature, both B- and T-cell immune responses play important role in ITP pathogenesis (Yuan et al., 2019). Depending upon the underlying cause, ITP can be classified into two subtypes – primary ITP (when no secondary cause is found) and secondary ITP when there is an underlying disorder that is linked with autoimmune destruction of platelets. The latter includes infections (Human immunodeficiency virus infection (HIV), Hepatitis C (HCV), and Helicobacter pylori), autoimmune diseases (like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), antiphospholipid antibody syndrome (APS)), and lymphoproliferative disorders like chronic lymphocytic leukemia (CLL) (Cines et al., 2009; Liebman, 2009). Most of the studies from developed countries have shown that 80% of cases of ITP are primary and the remaining 20% constitute secondary ITP. However, studies from developing countries suggest that secondary ITP is more common than primary (Kado & McCune, 2019; Sultan et al., 2016). This heterogeneity may be due to geographical variation and a higher incidence of infections in developing countries.

According to the time duration of diagnosis, ITP can be divided into three phases: newly diagnosed (0–3 months), persistent (>3 months to 12 months), and chronic phase (>12 months) (Rodeghiero et al., 2009). American society of hematology (ASH) and International Consensus have updated their guidelines in 2019 based on recent advances in ITP management (Neunert et al., 2019; Provan et al., 2019).
This review aims to summarize the contemporarily recommended diagnostic approach toward ITP and review the presently available treatment options.

**Investigations in the clinic and laboratory to rule out other possible pathophysiological explanations for ITP**

ITP is a diagnosis of exclusion and there is no gold standard test for its confirmation. Response to ITP-specific drugs (like corticosteroids and intravenous immune globulin (IVIG)) may support the diagnosis but does not fully exclude another disease with thrombocytopenia (Neunert et al., 2019; Audia et al., 2017). A detailed history, physical examination, and peripheral blood smear assessment by an experienced hematopathologist are crucial to diagnosing ITP. Apart from ITP, many other blood disorders can present with isolated thrombocytopenia (Provan et al., 2019).

**History and Physical Examination**

A detailed history of bleeding manifestations (especially menorrhagia in females), the severity of bleeding, prior blood transfusion, and any recent drug intake is essential. The severity of bleeding is graded with standard scales like the ITP Bleeding Scale (IBLS), ITP-specific Bleeding Assessment Tool (ITP-BAT), and WHO bleeding Scale. Although more precise, the clinical applicability of ITP-BAT is difficult in day-to-day practice due to the complexity of this scale. Contrarily, the WHO bleeding scale is simple to use and is validated for use in ITP patients (Rodeghiero et al., 2013; Fogarty et al., 2012). A family history of thrombocytopenia should be inquired to rule out familial thrombocytopenia. Many such patients with familial thrombocytopenia also have associated physical abnormalities and mental retardation. History of alcohol consumption, toxin exposure, and jaundice should be documented to rule out underlying chronic liver disease (Neunert et al., 2019; Provan et al., 2010; Bastida et al., 2019). Physical examination is crucial to diagnose specific disorders which can present with isolated thrombocytopenia (secondary ITP). Wet purpura may be the only sign of underlying thrombocytopenia (Mishra et al., 2017). Pallor may be present due to underlying anemia caused by blood loss. Jaundice may suggest underlying chronic liver disease or autoimmune hemolytic anemia (Evans syndrome). The presence of lymphadenopathy, hepatosplenomegaly may be suggestive of lymphoproliferative disorders or acute leukemia (Neunert et al., 2019; Provan et al., 2019).

**Laboratory Investigations**

Isolated thrombocytopenia is the most common finding on routine hemograms in ITP patients. In addition, anemia may be present which is usually proportional to the magnitude of bleeding. If anemia is out of proportion to bleeding severity, other causes like nutritional deficiency should be ruled out. RBC indices (mean corpuscular volume (MCV) and red cell distribution width (RDW)) may provide clues regarding anemia arising from nutritional deficiency (vitamin B12, folic acid, and/or iron deficiency). Megaloblastic anemia can also present with thrombocytopenia. Peripheral blood smear should be checked by an expert pathologist (Ren et al., 2003; Tseng et al., 2014). Apart from isolated
thrombocytopenia, it generally shows no abnormality except large or giant platelets which may sometimes be found. Abnormalities on peripheral blood smear examination may help to diagnose other conditions inconsistent with ITP; like schistocytes in microangiopathic hemolytic anemia (MAHA), leukocyte inclusion bodies in myosin heavy chain 9–related disease (MYH-9), and blasts in acute leukemias (Wongrakpanich et al., 2016; Balduini et al., 2011; Hamad et al., 2020). Liver function tests and renal function tests should be routinely performed. Abnormal liver functions may be present in chronic liver disease. Lactate dehydrogenase (LDH) and serum haptoglobin may be done if there is suspicion of concomitant hemolysis.

**Fig.1- Approach to thrombocytopenia**

**Tests to rule out secondary ITP**

Once the diagnosis of ITP has been established, the next step is to differentiate between primary and secondary ITP. Guidelines suggest that certain basic investigations should be performed in all ITP patients and consideration for additional investigations should be guided by geographical region.

**Anti-nuclear antibodies (ANA)**

A positive antinuclear antibody (ANA) test can be seen in 33% of adult primary ITP patients and it portends an increased risk of chronicity (Altintas et al., 2007; Moulis et al., 2020). Most of the guidelines do not advise routine ANA testing, and it should ideally be considered if the clinical picture suggests underlying connective tissue disorder-like SLE (Neunert et al., 2019; Neunert & Cooper,
In Asian countries, as the prevalence of SLE is high, ANA testing should be routinely performed in every patient with isolated thrombocytopenia (Heng et al., 2011).

**H. pylori testing**

Urea breath test or the stool antigen test can be performed to detect H. pylori infection in ITP patients who present with dyspeptic symptoms, especially in countries where there is a high prevalence of H. pylori. Some studies have shown improvement in platelet count among ITP patients after H. pylori-specific treatment (Sheema et al., 2017; Frdman et al., 2015).

**HIV, HCV, and HBV**

HIV and HCV infections are well-established causes of secondary ITP. Thrombocytopenia can be present for several years before the onset of symptoms due to the basic disease. Treatment of underlying viral infection corrects thrombocytopenia in a significant proportion of such patients (Varma et al., 2011; Franchini et al., 2017). Hence, routine testing of HIV and HCV is performed in all ITP patients. Testing for hepatitis B virus (HBV) can be done in the regions with its high prevalence and before rituximab therapy (Joo et al., 2017).

**Bone marrow examination**

Routine bone marrow investigation in a typical instance of ITP is not indicated. It can be considered if there is an uncertainty in clinical diagnosis, before splenectomy, or before commencing a new therapy. If completed, a bone marrow sample should be submitted for flow cytometry, and cytogenetic analysis to rule out lymphoproliferative diseases, myelodysplastic syndrome, and other primary bone marrow illnesses. A typical bone marrow aspirate of an ITP patient displays megakaryocyte hyperplasia with normocellular marrow (Tang et al., 2017; Ahmad et al., 2017).

**Ancillary Investigations (Case-To-Case Basis)**

**Direct anti-globulin test (DAT)**

One study revealed that up to 20% of ITP patients can have DAT positivity without evidence of hemolysis. However, in routine clinical practice, DAT testing is not advised. It must be performed in ITP patients with clinical or laboratory evidence of hemolysis, and before the use of anti-D therapy (Salama et al., 1984).

**Quantification of immunoglobulin levels**

Routine assessment of immunoglobulin profile is not advised. However, it is indicated when the index of suspicion for an underlying primary immunodeficiency disorder is high, and it should be done before intravenous immunoglobulin therapy.

**Blood group and Rh (D) typing**

It must be performed before anti-D therapy (Salama et al., 1984).
**Coagulogram**

It can be assessed if there is a suspicion of underlying disseminated intravascular coagulopathy (DIC), especially in hospitalized critically ill patients. In an outpatient setting, coagulogram testing has no role.

**Anti-platelet antibodies**

Anti-platelet antibodies to surface glycoproteins are observed in 50–60% of ITP patients. Testing for these antibodies has no role in routine clinical practice (McMillan, 2003). Old ELISA-based tests with low sensitivity and high specificity can be used in difficult cases to support the diagnosis of ITP. Newer techniques using glycoprotein-specific assays have better sensitivity and may be useful to guide ITP treatment in the future (McMillan, 2009; Chan et al., 2003; Sahu et al., 2020).

**Anti-phospholipid antibodies**

Anti-phospholipid antibodies (ACA) and lupus anticoagulant (LA) have been found in 25 to 46 percent of individuals with ITP in various investigations. Treatment with ITP is unaffected by their existence (Stasi et al., 1994; Pierrot et al., 2008; Yang et al., 2011). In the absence of any symptoms, regular testing is thus not advised.

**Thyroid function tests and anti-thyroid peroxidase (Anti-TPO)**

Mild thrombocytopenia is found in both hyperthyroidism and hypothyroidism, and it improves after achieving a euthyroid state. It is not clear whether autoimmune thyroid dysfunction is the cause of thrombocytopenia in ITP or incidentally related to ITP (Marta et al., 2015; Loachimescu et al., 2007; Cheung & Liebman, 2009). Although anti-TPO antibodies are commonly observed in ITP patients, they do not have any prognostic significance (Giordano et al., 2019). Thyroid function tests should not be performed routinely in ITP patients (Neunert et al., 2019). They can be performed in patients with clinical features of thyroid disease or in geographical areas where the prevalence of thyroid disorders is high.

**Thrombopoietin level**

Thrombopoietin level is normal in ITP patients and should not be routinely performed. It is increased in patients with bone marrow failure syndromes.

**Platelet’s indices**

There is no standardisation or routine recommendation for using platelet indices such as mean platelet volume, platelet distribution width, and reticulated platelets to diagnose ITP. In ITP and MDS patients, Tang et al. looked at the relationship between MPV and platelet count. When it comes to ITP, the platelet count has a strong correlation with MPV, but the reverse is true.(Tang et al., 2017; Giordano et al., 2019)

**Platelet function**

Platelet function assessment (Thromboelastographic (TEG), rotational thermoelectrometry (ROTEM), or Sonoclot) is helpful in the diagnosis and
treatment of ITP. However, these are not routinely recommended at present (Mishra et al., 2018; Mishra et al., 2017).

**First-Line Therapy for ITP**

The goals of treatment in ITP are: i) To achieve a safe platelet count (>30 × 10^9/L) to stop active bleeding and prevent future bleeding, ii) To achieve the good health-related quality of life so that patient can live a normal life, and iii) To prevent adverse effects of ITP-specific therapy.

**Glucocorticoids**

Patients with acute ITP are often treated with glucocorticoids. Steroids' mode of action is still a mystery. Antibody-producing lymphocytes may be inhibited, as well as macrophages, which are responsible for platelet phagocytosis, by steroids. (Provan et al., 2019; Mizutani et al., 1992) Most common regimen is oral prednisone or prednisolone (dose 0.5 mg to 2 mg/kg/day) (Neunert et al., 2019; Provan et al., 2019; Provan et al., 2010). Improvement in platelet count is generally seen in the initial 2 weeks. For patients achieving response (usually platelet count >50 × 10^9/L), the corticosteroid should be tapered over the next 6–8 weeks. If there is no improvement by 2–4 weeks of treatment, the steroid should be tapered over the next 1–2 weeks. During tapering, platelet count may show a decreasing trend (Neunert et al., 2019; Provan et al., 2019; Provan et al., 2010). High-dose pulse of dexamethasone (40 mg OD oral or IV daily for 4 days, repeated after 2–4 weeks, up to 3–4 cycles) can be used in place of oral prednisolone (Cheng et al., 2003; Borst et al., 2004). Multiple studies have compared the efficacy of prednisone and dexamethasone in ITP. A meta-analysis revealed that dexamethasone demonstrates a faster response (at 2 weeks) as compared to prednisolone, but there is no difference in outcomes at 6 months (Mithoowani et al., 2016). Intravenous methylprednisolone pulse (1 gm daily for 3 days, or 15 mg/kg/day), followed by oral prednisone 1 mg/kg/day from day 4 to sustain the response, is also used in the setting of acute ITP (Godeau et al., 2002; Godeau et al., 1995).

Initial response to corticosteroids takes 2 to 14 days, with peak response usually between 1 and 4 weeks (Figure 2). Although two-thirds of ITP patients achieve an initial response to glucocorticoids, the sustained response is seen in only 30%–50% of patients. Steroid-refractory ITP patients are candidates for second-line treatment options (Neunert et al., 2019; Provan et al., 2019; Provan et al., 2010; Neunert et al., 2011; Neylpon et al., 2003; Stasi et al., 1995). Glucocorticoid-based therapy needs supervision as they are associated with various adverse effects (Table 2). Intolerance to corticosteroids due to side effects is one of the indications to change therapy (Guirdy et al., 2009; Guirdy et al., 2009). Calcium and vitamin D supplementation are recommended to reduce the risk of osteoporosis. Bone mineral density (BMD) should be monitored with DEXA-scan in patients on steroids for a prolonged duration (Buckley et al., 2017). Patients with dyspeptic symptoms can be treated with proton-pump inhibitors or H2 antagonists (Messer et al., 1983).
Immunomodulatory Drugs

Intravenous immunoglobulin (IVIG)

Because of its anti-inflammatory and immunomodulatory properties, intravenous immunoglobulin (IVIG) is used to treat a wide range of autoimmune conditions. Most commercial preparations include immunoglobulin G (>95 percent weight-to-weight) and are derived from a plasma pool of over 1000 healthy donors. Primary or secondary antibody deficits were initially treated with this medication. High-dose IVIG was originally shown to enhance platelet counts in children with ITP in 1981 by Imbach et al. (Imbach et al., 1981). Since then, its efficacy in ITP is well established and it is used as first-line anti-ITP therapy, with or without steroids. IVIG blocks Fc receptors on phagocytic cells in the spleen and liver and prevents reticuloendothelial uptake of autoantibody-coated platelets. Another mechanism is the accelerated elimination of anti-platelet antibodies. The usual established dose is 1 gm/kg/ day for 2 days and it can be repeated at the same dose in non-responding patients. Initial high-dose IVIG has shown good response (67 vs. 21%) as compared to low dose, i.e., 0.5 mg/ kg/day (Lazarus & Crow, 2003; Lazarus, 2002).

Most ITP patients (70–80%) show improvement in 24 to 48 hours after IVIG and it is also used as a marker for diagnosis of ITP (Salib et al., 2016). The response is transient for 2–6 weeks and repeated doses may be needed to maintain a safe platelet count. As the response is faster than corticosteroids, IVIG can be used in emergencies like active bleeding with severe thrombocytopenia, or patients who need an urgent invasive procedure. About 30% of ITP patients become refractory to IVIG over time (Provan et al., 2010; Hong et al., 2018). Adverse reactions to IVIG include headache, hypertension, allergic reactions, etc., during administration. More serious adverse reactions include anaphylaxis in IgA deficient individuals, hemolytic anemia, acute kidney injury, thrombosis, and transmission of bloodstream infections (Ammann et al., 2016).

Anti-D immune globulin

The first-line treatment for ITP is anti-D immunoglobulin. An intravenous injection of 50 to 75 g/kg/dose of D antigen-targeted immunoglobulin is used to treat Rh-negative patients. Anti-D-coated RBCs occupy macrophages’ Fc receptors, causing macrophage activation.(65). Hence, it can be exclusively given to Rh-positive ITP patients and is not effective in patients who have already undergone splenectomy (Cooper et al., 2009). Response to anti-D therapy can be expected in 24 to 48 hours (like IVIG) and generally sustains for 3 – 4 weeks. Overall response rate is 65% (Provan et al., 2010; Scaradavou et al., 1997; Nainthani et al., 2009). IVIG-like infusion reactions are the most common adverse effects; however, they can also cause hemolytic anemia from extravascular hemolysis of anti-D-coated RBCs and acute hemolytic transfusion reaction (AHTR) (Scaradavou et al., 1997; Freiberg et al., 1998). So, patients should be monitored for 4 to 6 hours after anti-D infusion for flank pain, hematuria, and fever. Life-threatening intravascular hemolysis, DIC, and acute renal failure leading to death have been reported with anti-D, making it a less preferred alternative vis-à-vis IVIG (Gaines, 2000; Hong et al., 1998).
**Second-line therapy for ITP**

In the majority of adult ITP patients, glucocorticoids or IVIG have an immediate effect, but the platelet count does not remain stable for lengthy periods of time or recur later in life. The second-line treatment choices for these individuals may be categorised as medical (rituximab, thrombopoietin receptor agonists [TPO-RAs]) and are followed by a well-informed and cooperative decision-making process when picking the second-line drugs for the patients who failed upfront therapy.

**Rituximab**

It is a chimeric monoclonal antibody against CD20 on the surface of B-lymphocytes. It decreases B-cell function through multiple mechanisms like direct apoptosis, antibody-dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), augmentation of Th2 helper cells, and increase in regulatory T cells (Khellaf *et al.*, 2013). Its standard dose is 375 mg/m²/week (intravenous infusion) for 4 weeks. Similar efficacy has been achieved with alternative dosing schedules like 100 mg/week for 4 weeks, or 1000 mg on day 1 and day 15 (Neunert *et al.*, 2019; Provan *et al.*, 2019; Neunert *et al.*, 2018; Cragg *et al.*, 2005; Zaja *et al.*, 2010; Mishra *et al.*, 2020). Studies with rituximab in ITP have shown a response rate of 60–80% at 6 to 12 months, and 20–30% at 2–5 years (Provan *et al.*, 2019; Cheng *et al.*, 2011; Tran *et al.*, 2014; Miyakawa *et al.*, 2015; Marangon...
et al., 2017; Ghanima et al., 2015). Factors associated with poor response are the long duration of disease and failed previous attempts at treatment. Young female patients (<40 years) with newly diagnosed ITP show superior response to rituximab. Response rates among splenectomies and non-splenectomized patients are similar; however, relapses are frequent in splenectomized patients (Mishra et al., 2020; Sys et al., 2017; Pasa et al., 2009; Hindilerden et al., 2017; Qu et al., 2020). Infusion-related reactions are common with rituximab; therefore, the first infusion should always be given following a test dose and premedication with paracetamol and antihistamines (Des). Long-term side effects include increased risk of infections, late-onset neutropenia, reactivation of hepatitis B, hypogammaglobulinemia, and very rarely, progressive multifocal leukoencephalopathy (PMLE) (Paul et al., 2019). Testing for hepatitis B (HBsAg and anti-HBc (hepatitis-B core antibody)) is recommended before starting rituximab (Mishra et al., 2020; Hindilerden et al., 2017; Sahu et al., 2019; Focosi et al., 2019).

**Thrombopoietin receptor agonists (TPO-RAs)**

Thrombopoietin receptor agonists (TPO-RAs) are small molecules (peptide and non-peptide) that stimulate the production of megakaryocytes by activating the TPO receptors on bone marrow progenitor cells. Most patients with severe and symptomatic thrombocytopenia refractory to glucocorticoids or IVIG respond to TPO-RAs. They require continued therapy to sustain the response. TPO-RAs approved for ITP are eltrombopag, Romiplostim and avatrombopag.

**Eltrombopag**

Eltrombopag, a non-peptide oral medication licenced for chronic ITP, is usually begun at a dosage of 50 mg once day (maximum 75 mg/day). A lesser dosage might be prescribed to patients of Asian descent (25 mg once daily)(Tomiyama et al., 2012; Mishra et al., 2020). It should be taken 2 hours before or 4 hours after meals and drugs which contain polyanions (calcium supplements, antacids), for its maximum absorption (Saleh et al., 2013). Platelet count starts increasing after 1–2 weeks of therapy. In previous studies, 40%–80% of ITP patients were able to achieve the target platelet count. After discontinuation, 10–30% ITP patients continued to remain in remission (Cheng et al., 2011; Mishra et al., 2020; Saleh et al., 2013, Bussel et al., 2009; Copper et al., 2019). Short-term side effects include thrombocytosis, gastrointestinal discomfort, headache, and liver dysfunction. Liver function tests should be monitored regularly in patients on eltrombopag. Long-term and rare side effects include thrombosis, hepatic, and bone marrow fibrosis (Saleh et al., 2013; Ghanima et al., 2014). Some studies have shown worsening of renal failure when it is used in patients with systemic lupus erythematosus (Sperati & Streiff, 2010). Other studies did not show any major safety concerns with the drug (Ghanima et al., 2014; Cheng, 2013).

**Romiplostim**

It is a peptide, i.e. a recombinant protein, that has a peptide with four binding sites for the TPO receptor, linked to an IgG1- Fc component (Newland et al., 2006; Molimeux & Newland, 2010). It is given as a subcutaneous injection (1–10
µg/kg/week) (Cooper et al., 2019; Kuter et al., 2010; Cines et al., 2017). Response rates and the onset of action with romiplostim are similar to eltrombopag (Table 2). The sustained remission after stopping romiplostim is observed in 10–30% of patients (Cooper et al., 2019; Shirasugi et al., 2011; Bidika et al., 2020; Puravilai et al., 2020). A recent study from the United States has shown an overall response rate of more than 90% with romiplostim, which inversely correlated with the duration of ITP (Kuter et al., 2013). Mild headache, thrombocytosis, thrombosis, and reversible increase in bone marrow reticulin or collagen are the most common adverse effects (Janssens et al., 2016).

**Avatrombopag**

It is an oral preparation-like eltrombopag and it is usually started at 20 mg daily. Unlike eltrombopag, there is no need for any dietary restriction, and it can be taken any time after meals (Provan et al., 2019; Cooper et al., 2019; Jurczak et al., 2018; Dlugosz-Danecka et al., 2019). As compared to the other two TPO-RAs, there is less clinical experience with eltrombopag. Usually, platelets start increasing after 1–2 weeks of therapy with an overall response of 50–80%, which is dose-dependent (Neunert et al., 2019; Cooper et al., 2019; Jurezak et al., 2018; Dlugosz-Danecka et al., 2019; Bussel et al., 2014). Side effects similar to other TPO-RAs have been reported with eltrombopag which are easily manageable (Cooper et al., 2019; Xu et al., 2019). Switching between thrombopoietin receptor agonists (TPO-RAs) – Switching between eltrombopag to romiplostim or vice versa has been shown promising results and can be done in clinical practice. The most common reasons for switching are side effects of the drug, failure of one drug, and patient preference (Khellaf et al., 2013; Gonzalez-Porras et al., 2015).

**Splenectomy**

It is an option for patients not responding to corticosteroids or IVIG. It was a popular approach in the past, but less preferred nowadays due to the availability of effective non-surgical therapeutic options (Sys et al., 2017). The spleen is the major site of the platelet phagocytosis in ITP and its removal results in an improvement in platelet count. Splenectomy also removes lymphocytes which are responsible for the production of anti-platelet antibodies (Chater et al., 2016; Rodeghiero et al., 2018). Platelet count shows improvement in 1–8 weeks. In the short term, the response is seen in 80–90% of patients, and 60–70% of patients show sustained response over 5–10 years (Wu et al., 2004). Younger patients respond better to splenectomy than older patients (usually >65 years); no other factor can predict the response (George et al., 1996; Kojouri et al., 2004; Ojima et al., 2006; Fabris et al., 2001).

Most guidelines suggest splenectomy after 12 to 24 months of ITP diagnosis as some of these patients have a chance of spontaneous remission. So, we can avoid unnecessary major surgical procedures in a small subgroup of ITP patients. As such low platelet count is not a contraindication for splenectomy, but it should be maintained more than 50 × 109/L before the procedure, and it can be achieved by a short course of TPO-RAs or corticosteroids before splenectomy (Chen et al., 2011; Zaja et al., 2016; Kashiwagi et al., 2020). Laparoscopic splenectomy is preferred over open splenectomy due to less procedural complications (0.2% vs
1%) and morbidity (less hospitalization, early mobility) with the laparoscopic approach. Presently, laparoscopic splenectomy is the standard procedure in most of the centers (Kojouri et al., 2004; Duperier et al., 2004; Aramaki et al., 2003; Sotomayor-Ramirez, 2009). Procedural complications include infections, bleeding, thrombocytosis (9–12.9%), and 0.2% mortality risk during operation. Long-term complications include an increased risk of opportunistic infections (OPSI, lifetime risk 10%), arterial or venous thrombosis, and pulmonary hypertension. Old age is associated with more complications (Provan et al., 2010; Sys et al., 2017; Park et al., 2016; Vianelli et al., 2005; Tada et al., 2018). Patients planned for splenectomy should be immunized against encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, and meningococcal), ideally 2 weeks before the surgery. They should also receive the annual seasonal influenza vaccine and all other vaccines as recommended for their age. Post-splenectomy patients should be started empirically on an empirical antibiotic in case of febrile illness and should receive prophylactic antibiotics during procedures that involve paranasal sinuses or respiratory tract (Gillis et al., 1993; Buzele et al., 2016; McCrae, 2013; Nazi et al., 2013).

**Drugs after First and Second-Line Therapy**

**Fostamatinib**

For ITP patients who have failed first or second-line therapy or are unable to tolerate these medications, the FDA has authorised a new drug. TKI (tyrosine kinase inhibitor) is an oral medication that inhibits the activity of splenic tyrosine kinase in the body (SYK inhibitor) (Newland et al., 2018; Niscola et al., 2018). It is the active component (R406) that blocks signal transduction through Fc-activating receptors and the B-cell receptor and prevents phagocytosis of platelets coated with antibodies in the spleen. Its starting dose is 75 mg twice daily, which can be increased to 150 mg twice daily, depending upon the response (Moore et al., 2019; Bussel et al., 2018). The response rate varies from 18% to 43% in ITP patients previously treated with first and second-line drugs. Platelets usually start increasing in 1–2 weeks (Provan et al., 2019; Copper et al., 2019). Side-effects are mild and well-tolerated – like hypertension, liver dysfunction, nausea, and diarrhea. Blood pressure and liver functions tests need regular monitoring (Provan et al., 2019; Copper et al., 2019; Bussel et al., 2019).

**Immunosuppressive Therapy**

**Danazol**

It is frequently used as a steroid-sparing agent for ITP patients who are either intolerant to or non-affording for second-line drugs. Usual dose is 600–800 mg/day (Provan et al., 2019; Provan et al., 2010; Ahm et al., 1989). Published studies have shown response rates of 30–60% after 1–3 months. If there is no improvement in platelet count after 3 months of therapy, it can be stopped (Provan et al., 2019; Provan et al., 2010; Phillips et al., 1990; Liu et al., 2016). It is an androgenic drug and should not be used in patients with prostate cancer. Major side effects are acne, hirsutism, amenorrhea, and liver dysfunction (Provan et al., 2019; Provan et al., 2010; Liu et al., 2016; Schiavotto et al., 1993).
**Dapsone**

It is an oral sulfa drug with steroid-sparing action in ITP. It is started at a dose of 75–100 mg/day (Rattanathammethee et al., 2017). It has been used in the past as a cheap second-line treatment option for ITP in developing countries (Provan et al., 2010; Zaja et al., 2012; VancineCalifani et al., 2008). Platelet count starts improving after 3–4 weeks with an overall response rate of 30–60%. ITP patients who have already undergone splenectomy show inferior response to dapsone (Provan et al., 2019; Copper et al., 2019; VancineCalifani et al., 2008; Khera et al., 2020). Common side effects include gastrointestinal discomfort, headache, insomnia, methemoglobinemia, and hemolytic anemia in men with G6PD deficiency (Sahu et al., 2020). It should not be used in patients who are allergic to sulfonamides (Copper et al., 2019; Molineli et al., 2019).

**Azathioprine**

It is used at a dose of 1–2 mg/kg/day (maximum 150 mg/day). Response rates vary from 30% to 60% and are usually observed within 6–12 weeks (Copper et al., 2019; Chang et al., 2018). Although it is well-tolerated, rarely patients may develop liver dysfunction and neutropenia. With long-term use, there is the risk of developing leukemia with this drug (Yenson et al., 2008).

**Mycophenolate mofetil (MMF)**

It is an immunosuppressant drug, mainly used to prevent solid organ transplant rejection (Staaz et al., 2014). Its starting dose is 500 mg twice daily for 2 weeks which can be increased to 1 g twice daily. Improvement starts in 1–2 months and response can be seen in 30 to 60% of patients. Side effects are diarrhea, headache, increased risk of fungal infection, and increased risk of cancer (Copper et al., 2019; Taylor et al., 2015; Colovic et al., 2011; Hou et al., 2003).

**Cyclosporin**

In ITP patients, it can be taken alone or in combination with prednisone at a daily dosage of 2.5-3 mg/kg. In up to 80% of ITP patients, platelet count improvement has been observed, with a full response in 42% of patients. These include renal failure, hypertension, hirsutism and gum hypertrophy. For the sake of safety, it should be avoided in patients with renal failure, and therapeutic drugs should be closely monitored.(Emilia et al., 1996; Emilia et al., 2002; Kappers-Klunne et al., 2001)

**Cyclophosphamide**

It is uncommonly used nowadays in ITP. It can be given either orally (1–2 mg/kg/day) for at least 3–4 months or intravenously (0.3–1 g/m2/every 2–4 weeks) in ITP patients who are refractory to first or second-line therapy. Clinical response is seen in 24–85% of patients. Side effects include hemorrhagic cystitis, renal dysfunction, fatigue, neutropenia, and a rarely increased risk of acute myeloid leukemia (Verlin et al., 1976; Reiner et al., 1995; Reid et al., 1995; Krause et al., 1982; Sahu et al., 2016).
Vinca alkaloids (vincristine and vinblastine)

These drugs can achieve transient improvement in ITP with a variable response rate (10–75%). A weekly regimen for 2–3 weeks is commonly used (vincristine 1–2 mg/week and vinblastine 10 mg/week). Side effects include neuropathy, constipation, and local complications due to extravasation during infusion (Stirnemann et al., 2016; Park et al., 2016; Shvidel et al., 2006).

Combination Therapy In Newly Diagnosed And Refractory Itp

It includes the use of more than one agent for the treatment of refractory ITP (in whom first and second-line therapies have failed) or newly diagnosed ITP (as first-line therapy). Doublet and triplet regimens in such settings have shown encouraging results. Studies have shown that upfront combination therapies comprising of recombinant TPO-RAs and steroids lead to superior outcomes in terms of response rates as compared to monotherapy (Zhou et al., 2015; Arai et al., 2018). However, it is important to note the difference between the real-world experience and differentiate it from the investigations and trials done in laboratory settings. Many patients when they get enrolled in trials, undergo washout periods in which they are not given any therapy for a few weeks and then treated in a naïve setting with a combination of investigational drugs while investigators watch what happens to the platelet count. Also, when investigating a combination treatment, another factor that deserves attention is that patient satisfaction and quality of life.

Triple Therapy

It includes low-dose rituximab (100 mg on days 7, 14, 21, and 28), high-dose oral dexamethasone (40 mg daily on days 1–4), and oral cyclosporin (2.5 to 3 mg/kg daily on days 1–28) for a total duration of 4 weeks. It is also called TT4, i.e. triple therapy for 4 weeks, and has a response rate of 60% at 6 months (Choi et al., 2015). Another combination of oral azathioprine, cyclosporin, and mycophenolate has shown a response rate of 70%, but more than 50% of patients relapsed on subsequent follow-up (Arnold et al., 2010; Figueroa et al., 1993).

Doublet Regimen

Dexamethasone and rituximab combination or TO-RAs and dexamethasone have been tried in newly diagnosed ITP patients with a higher sustained response rate than dexamethasone alone (58% vs 37%) (Gudbrandsdottir et al., 2013). Studies have also shown superior and faster response to combinations of IVIG and steroids than either of these drugs alone (Gudbrandsdottir et al., 2013; Zaja et al., 2010; Boruchov et al., 2007). A recently conducted multicenter, UK-based, open-label, randomized controlled trial (The FLIGHT trial) compared combined MMF and corticosteroid versus corticosteroid alone and found it to be a more effective first-line ITP treatment. Although there were almost similar rates of significant adverse events, and bleeding events between the two groups, some aspects of QoL were noted to be worse in MMF plus steroid group. A recently concluded study (ClinicalTrials.gov Identifier: NCT00909077) compared high-dose dexamethasone versus high-dose dexamethasone in combination with rituximab. This was a
randomized phase III study involving 155 newly diagnosed patients with ITP. It was noted that patients with rituximab + dexamethasone had a sustained response at 6 months follow-up (i.e. platelets ≥50 × 10^6/L) when compared with the dexamethasone alone group (58% versus 37%, P = .02) (Gudbrandsdottir et al., 2013). Similarly, Eltrombopag plus dexamethasone (Dose, Eltrombopag 50 mg PO days 5–32 Dexamethasone 40 mg PO days 1–4) (ClinicalTrials.gov identifier: NCT01652599). They found that 100% of patients got a response of platelet count ≥ 30 × 10^9/L at the end of Day 33. Also, a sustained response of platelet count ≥ 50 × 10^9/l at 6 months was noted in 75% of these patients. The combination treatment was well tolerated without any ill events of myelofibrosis, or thrombosis.

**Supportive Care During Active Bleed**

**Platelet’s transfusion**

ITP is one of the most common indications for hematology consultation in an emergency (Nampoothiri et al., 2017). Platelet transfusion can be used as a temporary measure to tackle active bleeding in an emergency. Patients should be started on definite therapy as early as possible (Goel et al., 2019; Estcourt et al., 2017; Zhang et al., 2020). Platelet transfusion does not increase thrombotic risk (Goel et al., 2015).

**Anti-fibrinolytic drugs**

IV or oral tranexamic acid (15–20 mg/kg q 8 hourly), epsilon aminocaproic acid (1–5 gm 6 hourly) can be used as a short-term measure in an emergency but the long-term benefit of these drugs is not clear (Wardrop et al., 2013; Estcourt et al., 2016).

**Hormonal therapy**

Norethisterone can be used to stop menstrual bleeding in females for a short duration till definite therapy starts working (Lethaby et al., 2015; Bofill et al., 2019).

**Special Scenarios In ITP**

**ITP and pregnancy**

In pregnancy, differential diagnoses for thrombocytopenia include gestational thrombocytopenia, pregnancy-related hypertensive disorders like eclampsia, HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count). Once the diagnosis of ITP is established, the patient should be kept on close follow-up for bleeding with target platelet count >30 × 10^9/L till term. The mode of delivery is guided by the obstetrician’s choice. For normal delivery, the platelet count should be kept >50 × 10^9/L, and for the cesarean section, it should be maintained >70 × 10^9/L for safe spinal anesthesia. Drugs preferred in pregnancy are IVIG and corticosteroids. Patients are usually started on prednisolone at 20 mg daily and the patient is kept on a minimum dose to maintain target platelets to avoid unnecessary side effects. IVIG at dose 1–2 gm/kg can be used if a fast response is required near term. Anti-D can be also used in non-splenectomized patients after documenting negative direct Coombs test. In refractory cases, combination
therapies comprising of high-dose corticosteroid (dexamethasone) with IVIG or azathioprine, or cyclosporine with azathioprine can be used. The published experience with TPO-RAs in pregnancy is limited to case reports only. Rituximab increases the risk of immunosuppression in the newborn, so its use is not recommended. If a patient needs splenectomy for refractory ITP, it should be preferably performed during the second trimester. Vinca alkaloids, mycophenolate, and cyclophosphamide should not be used during pregnancy (Neurent et al., 2019; Provan et al., 2019; Provan et al., 2010; Eslick & McLintock, 2020).

**ITP and surgery**

Most of the minor and major surgeries can be performed without any significant bleeding complication at platelet count >50×10⁹/L and >80×10⁹/L, respectively. Neurosurgical intervention requires platelets count >100×10⁹/L (Neurent et al., 2019; Provan et al., 2019; Provan et al., 2010).

**ITP and anticoagulation**

For ITP patients who need anticoagulation for any reason, the platelet count should be maintained above 50×10⁹/L (Provan et al., 2019; Provan et al., 2010).

**Secondary ITP**

Once the cause of ITP has been detected, the treatment of the underlying disease should be started. Patients with HCV infection should be started with newer antiviral drugs. HIV-associated thrombocytopenia generally improves with antiretroviral therapy. Patients with a positive urea breath test should be treated for H. pylori infection. If there is no improvement after treating the underlying cause, the patients can be treated as primary ITP with IVIG or corticosteroids (Neurent et al., 2019; Provan et al., 2010; Neurent et al., 2011).

**Upcoming Therapy/Clinical Trials**

Newer drugs in ITP like Bruton Tyrosine kinase (BTK) inhibitors, anti-CD154 monoclonal antibody, and neonatal Fc Receptor (FcRn) are in phase 1/2 trials (Smith et al., 2018; Dou & Yang, 2019). Rilzabrutinib (a BTK inhibitor) has shown good activity in refractory ITP patients (presented as abstract in ASH 2020). The details of newer drugs that are currently being investigated for ITP are described in Table 3.

**Conclusion**

ITP is a heterogeneous disorder with unclear pathogenesis. The majority of the adult ITP patients (80%) progress to the chronic phase and need long-term follow-up. ITP is a diagnosis of exclusion and secondary causes for thrombocytopenia should be ruled out. All patients do not need therapy. The goal of therapy is to achieve and maintain a safe platelet count so that the patients can live a normal life. Corticosteroids and IVIG are the preferred first-line drugs. The role of TPO-RAs is evolving as second-line treatment. Splenectomy may be reserved for the patient’s refractory to medical treatment. This review is about the challenges in
the diagnosis and management of ITP. The current advancements are targeted to minimize the bleeding events and at the same time to keep the medication-related side effects to a minimum. It is important to note for the internists that bleeding events in ITP are not proportionally related to the severity of thrombocytopenia. Hence, there is the possibility that a severely thrombocytopenic patient can have a non-bleeding phenotype and alternatively, a moderately thrombocytopenic patient can have a bleeding phenotype. Most adult ITP patients progress to the chronic phase and need lifelong follow-up. Not all patients with ITP need therapy. Only those with platelet count less than 30 × 109/L or bleeding with thrombocytopenia require treatment. The goal of treatment is to achieve a safe platelet count with no bleeding symptoms. Corticosteroid or IVIG/Anti-RhD is usually the first-line therapy that yields a good response. Thrombopoietin receptors agonist (TPO-RAs) and rituximab can be used if first-line drugs fail. Splenectomy is an excellent one-time procedure that yields a long-term cure; however, it is less preferred in the modern era and generally reserved for refractory cases. Other medications like danazol, dapsone, cyclosporine, mycophenolate mofetil can be used in patients who fail the previous two lines of therapy. Combination therapy with two or more drugs is also an option for relapsed/refractory cases. New drugs like Bruton’s tyrosine kinase (BTK) inhibitors have shown excellent response in the phase 1/2 trial. Many investigations on new drugs and other treatment modalities are going on in various clinical trials and are expected to bring newer insight into the management of ITP.

References


